AC

Accendra Health, Inc.

ACCH · NYSE · Healthcare / Medical Distribution

0.02USD

Price History

Full chart

Market Stats

Open0.02
Day Range0.02 – 0.02
52-Week Range0.01 – 0.44
Volume4.68M
Market Cap1.57M
P/E (TTM)0.00
Forward P/E6.94
EPS-1.60
Dividend Yield0.00%
Beta1.62
50-Day Avg0.4058
200-Day Avg2.08

About

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.

Company Details

  • SectorHealthcare
  • IndustryMedical Distribution
  • CEOMr. Kenneth Gardner-Smith
  • Employees6.50K
  • Headquarters4435 Waterfront Drive, Glen Allen, VA, United States, 23060, USA
  • Websitehttps://www.accendrahealth.com

Leadership

  • Mr. Kenneth Gardner-SmithPresident, CEO & Director · b. 1981
  • Mr. Jonathan A. LeonExecutive VP, CFO & Corporate Treasurer · b. 1967
  • Mr. Heath H. GallowayExecutive VP, General Counsel & Corporate Secretary · b. 1977
  • Mr. Perry A. BernocchiStrategic Advisor to the CEO · b. 1959
  • Mr. Nicholas PiecoraSenior VP & Chief Information Officer
  • Will ParrishVP of Strategy, Corporate Development, & IR
  • Ms. Carrie ChildressExecutive VP & Chief Marketing Officer
  • Mr. Dirk BensonChief Commercial Officer
  • Mr. Colin BainChief Products Officer
  • Ms. Agnes AnsayVP & Chief Procurement Officer

Financials

Income Statement

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Revenue9.96B2.55B2.68B2.76B
Growth (%)--74.36%+5.00%+3.06%
Cost of Revenue8.13B1.34B1.40B1.47B
Gross Profit1.83B1.22B1.28B1.29B
Gross Margin18.35%47.68%47.77%46.68%
Operating Expense1.55B1.00B1.08B1.07B
Operating Income276.78M215.36M198.04M221.74M
Operating Margin2.78%8.44%7.39%8.03%
EBITDA368.45M342.40M-41.04M219.75M
EBITDA Margin3.70%13.41%-1.53%7.96%
Net Income22.39M-41.30M-362.69M-1.10B
Net Income Margin0.22%-1.62%-13.53%-39.85%
Interest Expense128.89M116.77M107.57M107.18M
Interest Expense % of Total Revenue1.29%4.57%4.01%3.88%

Balance Sheet

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Assets5.39B5.09B4.66B2.45B
Total Liabilities4.44B4.17B4.07B2.91B
Total Equity945.60M924.17M586.36M-460.98M
Cash69.47M243.04M27.57M281.99M
Net Debt2.43B1.85B1.81B1.77B

Cash Flow

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow325.01M740.71M161.50M-101.79M
Financing Cash Flow1.50B-411.06M-250.02M190.21M
Capital Expenditure166.58M178.53M182.66M201.32M
Free Cash Flow158.42M562.18M-21.17M-303.12M
Dividends Paid00--
FCF to OCF48.74%75.90%-13.11%297.78%
Dividend Paid to FCF0.00%0.00%--

Earnings

Report DateDec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
EPS Estimate0.22-0.10-0.09-0.09
EPS Actual0.21-0.04-0.19-0.23
Surprise-5.15%59.31%-115.91%-151.64%
Timing----

Key Statistics & Ratios

Market Cap1.57M
Enterprise Value1.79B
Trailing P/E0.00
Forward P/E6.94
Price / Sales0.00
Price / Book1.07
EPS-1.60
Book Value-7.39
Revenue (TTM)2.55B
Gross Profit (TTM)1.13B
EBITDA242.79M
Profit Margin-6.72%
Operating Margin0.47%
Return on Equity0.00%
Return on Assets0.24%
Shares Outstanding76.97M
Shares Float56.22M
Beta1.62
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Sell
Based on 3 analystsTarget 1.40
  • Hold
    1
  • Sell
    2